Why the study?
It was important to determine whether the treatment-induced early eGFR decline with dapagliflozin, spironolactone, or their combination reflects kidney injury or merely hemodynamic changes.
Does the combination of dapagliflozin and spironolactone cause true kidney injury compared to either drug alone in patients with HFmr/pEF?
Does the combination of dapagliflozin and spironolactone cause true kidney injury compared to either drug alone in patients with HFmr/pEF?
Answers are grounded in this paper and cite their sources.
In patients with HFmr/pEF, the combination of dapagliflozin and spironolactone reduces blood pressure and eGFR more than either drug alone at 12 weeks, prompting investigation into whether this represents true kidney injury or transient hemodynamic changes.
Disease-modifying treatments for heart failure with mildly reduced or preserved ejection fraction (HFmr/pEF), such as sodium-glucose co-transporter 2 inhibitors (SGLT2i) and mineralocorticoid receptor antagonists (MRAs), induce a transient early decline in estimated glomerular filtration rate (eGFR) that has been called the eGFR ‘dip’.1,2 Such eGFR ‘dip’ usually lasts for 2 to 3 months after therapy initiation with a slow recovery thereafter. This treatment-associated eGFR decline is thought to be induced by systemic and intraglomerular hemodynamic changes without ‘true’ kidney injury. As SGLT2i and MRAs, in particular, reduce blood pressure (BP) they may influence kidney hemodynamics, especially in elderly HFpEF populations whose kidney pressure-mediated autoregulation may be impaired.3 In SOGALDI-PEF (Dapagliflozin With or Without Spironolactone for HFpEF; NCT05676684), the dapagliflozin/spironolactone combination reduced BP and eGFR more than dapagliflozin or spironolactone alone at 12 weeks.4 As eGFR decline may have clinical importance and lead to therapeutic changes (e.g. treatment withdrawal), it is important to study whether such treatment-induced eGFR decline reflects kidney injury or simply hemodynamic or transient changes in creatinine filtration and reabsorption without major clinical significance i.e. requiring no therapeutic action other than eGFR monitoring.
No takes yet. Share an insight, caveat, or question.
Ferreira et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: